Jennifer Levin Carter, MD, MPH, MBA

Board of Directors

Jennifer Levin Carter, MD, MPH, MBA is Founder and CEO of Medzown, Inc., a Precision Medicine Management Company.

Dr. Carter was formerly a Managing Partner and Venture Partner at Sandbox Industries and Blue Venture Fund. The Blue Venture Fund is a unique collaboration between BCBS companies, BCBSA, and Sandbox. Dr. Carter is a healthcare executive, investor, board member, and entrepreneur with a successful track record of developing and investing in innovative strategies and solutions at the intersection of and healthcare IT and services, digital health and machine learning, precision medicine, genomics and its application to healthcare delivery and life sciences including novel clinical trial delivery and drug development. Dr. Carter has deep expertise in creation and implementation of systems and platforms using next generation data and technology to support patient and physician access to improved therapeutic strategies.

Prior to Sandbox and Blue Venture Fund, she was Managing Director of JLC Precision Health Strategies. Prior to this, Dr. Carter was VP and Head of Precision Health at Integral Health (now Valo Health), a Flagship Pioneering company. In 2018, she founded a novel clinical trials company in stealth, and was CEO until it’s prelaunch acquisition by Integral Health in March 2019. Prior to the clinical trials company, Dr. Carter was the Founder and President of N-of-One®, Inc. She served as CEO from 2008-2012, and President and Chief Medical Officer from 2012 until its acquisition by Qiagen (Market Cap $8B) in 2019. At N-of-One, Dr. Carter led the creation of award-winning solutions that still deliver novel treatment strategies to hundreds of thousands of patients with cancer globally.

Dr. Carter is on the Board of Directors of, TempraMed, Inc., and Target Cancer Foundation. She was previously on the Board of Directors of Oncocyte (NASDAQ: OCX) serving on the Science (Chair) and Audit Committees, Compensation (Chair), Finance (Chair); XSphera Biosciences, Inc. (Co-Founder and Board of Directors); CareMax (NASDAQ: CMAX) serving on the Compliance (Chair) and Compensation Committees; and DFP Healthcare Acquisitions Corp (NASDAQ: DFPH); HouseWorks, LLC (acquired in 12/22); eCaring (acquired, 12/22). Dr. Carter is on the Director’s Advisory Board at Smilow New Haven Cancer Center at Yale University, the Board of the Blavatnik Fund at Yale University, and the MedExec Women’s Advisory Board. She is a strategic advisor and consultant to numerous healthcare and life sciences startups and venture-backed companies on strategy, product development, business model design and fund raising. She is a member of American Association of Corporate Directors (Advanced Professional Director Certification); National Academy of Corporate Directors (New England Chapter Private Board Programming Committee); Women Corporate Directors; Women Business Leaders of the U.S. Health Care Industry Foundation, and Women in Bio. Dr. Carter has participated as a presenter, expert panelist, or moderator at numerous industry conferences, events, and symposiums, and has served on multiple industry advisory boards.

Prior to founding and leading N-of-One®, Dr. Carter spent nine years working as an Investment Consultant specializing in biotechnology, healthcare services and life sciences investments evaluating existing and emerging markets, new medical technologies, and early-stage companies. After obtaining her MD, Jennifer practiced internal medicine at Mount Auburn Hospital in Cambridge, MA.

Dr. Carter graduated Phi Beta Kappa, Summa Cum Laude with distinction with a BS in Molecular Biophysics and Biochemistry from Yale University, an MD from Harvard Medical School, an MPH from Harvard School of Public Health, and an MBA from the Sloan School of Management at Massachusetts Institute of Technology.